The cash received from this transaction together with the savings from future expenses, after making a partial prepayment on EpiCept's existing term loan with MidCap Financial LLC of approximately $0.8 million, will enable EpiCept to operate into the (fourth quarter 2012) without further financing.the most in important here is the trial AmiKet™ . long time inverter in this crappy company need sell at $2.50 just to break even so im hostage right now but if amiket passes in america its could jump to $15.00 big pharma likes new painkillers people always get addicted to them and they will pay top dollar for it peace out.
After todays news the Ceplene rights is fully in the hands of Epicept, but a geographical part (The EU and RIM-countries) and the production for these markets and the costs for the post approval study in the EU now is taken by Meda.
Their is a more specified patientgroup for Ceplene after the latest results from Thorén et al (www.Pubmed.com)
I wait for some initiatives from management concerning KOLs and the pathway forward for a new trial design in the US for Ceplene.
No PP, but new deals seems to be next step. The Edison report is reasonable.